In multidrug-resistant lymphoma cell lines expressing a higher levels of Tiam1, the researchers found that dual inhibition of Tiam1-Rac1 and Notch pathways would be an important treatment for overcoming the resistance of lymphoma cells to adriamycin (146). The gene discussed is RAC1; the disease is lymphoma.